ProActive Capital Resources Group, a company dedicated to the discovery and creation of value in the small and micro-cap marketplace, is proud to announce client presentations at the 3rd Annual OneMedForum held in San Francisco, January 12-13, 2010. ProActive clients presenting are: Access Pharmaceuticals, ImmunoCellular Therapeutics, DataTrak International, Quantum Immunologics, with Protox Therapeutic's presentation pending.
DataTrak International, Inc. is presenting on Wednesday, January 13, 2010 at 9:45 AM. Mike Havrilla reports: "DataTrak is a clinical trials information technology and services company that is focused on increasing its share of an estimated $720 million Electronic Data Capture (EDC) market opportunity (with about 50% of this market still utilizing paper records that have yet to convert to make the digital conversion)" (http://www.proactivenewsroom.com/datatrak-datapk/)
Access Pharmaceuticals, Inc. is presenting on Wednesday, January 13, 2010 at 3:00 PM. Access Pharma is an emerging bio-pharmaceutical company which is focusing on the development of a late-stage, diversified oncology pipeline in addition to a treatment called MuGard that is cleared for marketing in major global markets for a common side effect of some cancer treatments known as mucositis. BioMedReports.com (www.biomedreports.com) hosts an article by Mike Havrilla, http://tiny.cc/LiBIR.
Quantum Immunologics (QI) is a privately held company and is presenting on Wednesday, January 13, 2010 at 4:00 PM. QI is dedicated to improving the treatment outcome and quality of life for cancer patients through the research, development, and commercialization of innovative, cost-effective therapeutic and diagnostic products that are based on a unifying theory that links the immunogenic and invasive properties of malignant cancers with a specific protein known as oncofetal antigen immature laminin receptor protein (OFA-iLRP). www.BioMedReports.com has a report on QI http://tiny.cc/qHkFk
ImmunoCellular Therapeutics, presenting on Wednesday, January 13, 2010 at 4:15 PM, is an emerging cancer immunotherapy company that is developing therapeutic and diagnostic product candidates taking aim at the root cause of the disease, cancer stem cells (CSCs), based on two distinct technology platforms -- active (cancer vaccines) and passive (monoclonal antibodies or MAbs). (http://www.onemedplace.com/blog/archives/3584)
Presentation Pending: Protox Therapeutics applies genetic engineering techniques to create innovative, targeted protein-based therapeutics which are focused on prostate conditions and cancer. In September, 2009 Protox was one of www.BioMedReports.com Extreme Stock Picks, http://tiny.cc/H0IPH Source:
New Alzheimer's guidelines focus on risk, not diagnosis, in healthy adults